•
PA
PASG
Passage Bio, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
39.16M
Volume
89.02K
52W High
$20.00
52W Low
$5.12
Open
$0.00
Prev Close
$12.77
Day Range
0.00 - 0.00
About Passage Bio, Inc. Common Stock
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Latest News
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034
GlobeNewswire Inc.•Oct 17
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
GlobeNewswire Inc.•Mar 4
Passage Bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.•Feb 26
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire Inc.•Nov 6
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire Inc.•Aug 30
Passage Bio Announces Positive Feedback from FDA on - GlobeNewswire
GlobeNewswire Inc.•Jul 16
Passage Bio (PASG) Loses -22.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research•Jun 18
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire Inc.•Jun 5